HER2-Low Breast Cancer: Pathological and Clinical LandscapePaolo Tarantino, Giuseppe Curigliano, Erika Hamilton et al.|Journal of Clinical Oncology|2020Cited by 801
Recent advances in triple negative breast cancer: the immunotherapy eraAntonio Marra, Giuseppe Curigliano, Giulia Viale|BMC Medicine|2019Cited by 378
Practical classification of triple-negative breast cancer: intratumoral heterogeneity, mechanisms of drug resistance, and novel therapiesAntonio Marra, Giuseppe Curigliano, Dario Trapani et al.|npj Breast Cancer|2020Cited by 319
Breast implant-associated anaplastic large cell lymphoma: A comprehensive reviewAntonio Marra, Giuseppe Curigliano, Giulia Viale et al.|Cancer Treatment Reviews|2020Cited by 122
Molecular Biomarkers of Disease Outcomes and Mechanisms of Acquired Resistance to First-Line Osimertinib in Advanced EGFR-Mutant Lung CancersNoura J. Choudhury, Helena A. Yu, Gregory J. Riely et al.|Journal of Thoracic Oncology|2022Cited by 95